Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report
Pharmaceuticals August 1, 2023 Boney Joseph, Nicolas A. Nunez, Simon Kung et al. 14 citations
Intravenous (IV) ketamine and FDA-approved intranasal (IN) esketamine are increasingly used for treatment-resistant depression (TRD). Preliminary studies have suggested a synergistic effect of ketamine and lamotrigine, although the data are inconclusive. Herein, we report the response to serial ketamine/esketamine treatment among patients with TRD with or without lamotrigine therapy. In this...